Bone metastases are measurable: the role of whole-body MRI and positron emission tomography
DE Oprea-Lager, MCF Cysouw, R Boellaard… - Frontiers in …, 2021 - frontiersin.org
Metastatic tumor deposits in bone marrow elicit differential bone responses that vary with the
type of malignancy. This results in either sclerotic, lytic, or mixed bone lesions, which can …
type of malignancy. This results in either sclerotic, lytic, or mixed bone lesions, which can …
The future of PSMA PET and WB MRI as next-generation imaging tools in prostate cancer
Y Wang, JR Galante, A Haroon, S Wan, A Afaq… - Nature Reviews …, 2022 - nature.com
Radiolabelled prostate-specific membrane antigen (PSMA)-based PET–CT has been shown
in numerous studies to be superior to conventional imaging in the detection of nodal or …
in numerous studies to be superior to conventional imaging in the detection of nodal or …
Flare on [18F]PSMA-1007 PET/CT after short-term androgen deprivation therapy and its correlation to FDG uptake: possible marker of tumor aggressiveness in …
S Malaspina, O Ettala, T Tolvanen, J Rajander… - European Journal of …, 2023 - Springer
Purpose Short-term androgen deprivation therapy (ADT) is known to increase
heterogeneously prostate-specific membrane antigen (PSMA) expression. This …
heterogeneously prostate-specific membrane antigen (PSMA) expression. This …
Osteoblastic bone reaction in non-small cell lung cancer harboring epidermal growth factor receptor mutation treated with osimertinib
K Kanaoka, H Sumikawa, S Oyamada, A Tamiya… - BMC cancer, 2023 - Springer
Background Osteoblastic bone reaction (OBR) refers to an increase in bone density at the
site of bone metastasis or the appearance of new sclerotic bone lesions after anticancer …
site of bone metastasis or the appearance of new sclerotic bone lesions after anticancer …
Prevalence and Prognostic Implications of PSA Flares during Radium-223 Treatment among Men with Metastatic Castration Resistant Prostate Cancer
A Sidhu, N Khan, C Phillips, J Briones… - Journal of Clinical …, 2023 - mdpi.com
Radium-223 (Ra233) prolongs the survival of men with symptomatic bone-predominant
metastatic castration-resistant prostate cancer (mCRPC). However, prostate-specific antigen …
metastatic castration-resistant prostate cancer (mCRPC). However, prostate-specific antigen …
Quantitative Assessment of Treatment Response in Metastatic Breast Cancer Patients by SPECT-CT Bone Imaging—Getting Closer to PET-CT
M Gherghe, MD Mutuleanu, AE Stanciu, I Irimescu… - Cancers, 2023 - mdpi.com
Simple Summary The aim of our study is to demonstrate the added value of the quantitative
interpretation of SPECT-CT images compared to qualitative assessment regarding changes …
interpretation of SPECT-CT images compared to qualitative assessment regarding changes …
Comparison of 18F-PSMA-1007 and 18F-Choline PET/CT in prostate cancer patients with biochemical recurrence: a phase 3, prospective, multicenter, randomized …
E Panagiotidis, V Fragkiadaki… - Nuclear Medicine …, 2023 - journals.lww.com
Objectives This prospective, multicenter, open-label, randomized, crossover trial study was
to evaluate the diagnostic performance of 18F-PSMA-1007 (PSMA) vs. 18F-Choline PET/CT …
to evaluate the diagnostic performance of 18F-PSMA-1007 (PSMA) vs. 18F-Choline PET/CT …
Early biochemical and radiographic response after one cycle of [177Lu]Lu-PSMA I&T radioligand therapy in metastatic castration-resistant prostate cancer patients
W Cytawa, R Hendel, B Tomasik, FX Weinzierl… - European Journal of …, 2023 - Springer
Purpose The aim of this study was to investigate very early radiographic PSMA PET
response after one cycle of [177Lu] Lu-PSMA I&T radioligand therapy (RLT) of metastatic …
response after one cycle of [177Lu] Lu-PSMA I&T radioligand therapy (RLT) of metastatic …
Nuclear medicine imaging for bone metastases assessment: what else besides bone scintigraphy in the era of personalized medicine?
E Ouvrard, A Kaseb, N Poterszman, C Porot… - Frontiers in …, 2024 - frontiersin.org
Accurate detection and reliable assessment of therapeutic responses in bone metastases
are imperative for guiding treatment decisions, preserving quality of life, and ultimately …
are imperative for guiding treatment decisions, preserving quality of life, and ultimately …
Personalizing approaches to the management of metastatic hormone sensitive prostate cancer: role of advanced imaging, genetics and therapeutics
SD Lokeshwar, AU Choksi, D Haltstuch… - World Journal of …, 2023 - Springer
Purpose To summarize contemporary and emerging strategies for the diagnosis and
management of metastatic hormone sensitive prostate cancer (mHSPC), focusing on …
management of metastatic hormone sensitive prostate cancer (mHSPC), focusing on …